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Epitranscriptome modifications are required for structure and function of RNA and defects in
these pathways have been associated with human disease. Here we identify the RNA target
for the previously uncharacterized 5-methylcytosine (m5C) methyltransferase NSun3 and link
m5C RNA modifications with energy metabolism. Using whole-exome sequencing, we
identified loss-of-function mutations in NSUN3 in a patient presenting with combined
mitochondrial respiratory chain complex deficiency. Patient-derived fibroblasts exhibit severe
defects in mitochondrial translation that can be rescued by exogenous expression of
NSun3. We show that NSun3 is required for deposition of m5C at the anticodon loop in the
mitochondrially encoded transfer RNA methionine (mt-tRNAMet). Further, we demonstrate
that m5C deficiency in mt-tRNAMet results in the lack of 5-formylcytosine (f5C) at the same
tRNA position. Our findings demonstrate that NSUN3 is necessary for efficient mitochondrial
translation and reveal that f5C in human mitochondrial RNA is generated by oxidative
processing of m5C.
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T
he mitochondrial metabolic pathway of oxidative
phosphorylation (OXPHOS) is composed of B90 protein
components, with 13 of them encoded by the
mitochondrial DNA (mtDNA) and translated within the
organelle. Defects in mitochondrial function caused by impaired
mitochondrial gene expression lead to a wide range of human
metabolic diseases. Impaired mitochondrial translation can stem
from mtDNA mutations in mitochondrial (mt-) tRNAs or, less
frequently, in mt-rRNA (ribosomal RNA). Mutations in nuclear
genes coding for enzymes responsible for mtRNA nucleotide
modifications, nucleolytic mtRNA processing, proteins involved
in mitochondrial ribosome biogenesis and mitochondrial
translation factors are also associated with a very rapidly
expanding group of human disorders1–3.
Of the over 100 known enzyme-catalysed modifications in
RNA, methylation is one of the most common4. The majority of
the methyl-based modifications are conserved from bacteria to
mammals and their functions include structural and metabolic
stabilization as well as functional roles in regulating protein
translation5,6. The existence of methylated nucleosides in RNA
such as 5-methylcytidine (m5C) has been described decades ago,
but the definition of their precise location, abundance and
cellular functions has commenced only recently7–9. Mammalian
genomes encode at least seven highly conserved RNA:m5C
methyltransferases of the NOL1/NOP2/Sun (NSun) domain-
containing family (NSun 1-7). Human NSun2 and NSun6 both
modify cytoplasmic tRNAs. NSun6 methylates position C72 of
tRNACys and tRNAThr (ref. 10), while NSun2 has a broader
spectrum, methylating various nuclear-encoded tRNAs at
positions C34, 48, 49 and 50 (ref. 11,12) as well as other
non-coding RNA species13,14. Yeast homologue of NSun5
methylates C2278 within a conserved region of the cytosolic
large (25S) rRNA and NSun5 orthologues in yeast, worms and
flies have been implicated in regulation of lifespan and stress
resistance15. Mouse NSun4 is localized in mitochondria and
methylates small (12S) mitochondrial rRNA, with a role in
coordinating mitoribosome assembly16.
Here we report mutations in a previously uncharacterized gene,
NSUN3. We confirm that in humans the protein is localized
in mitochondria17 and show that it is required for methylation
of mt-tRNAMet at the wobble base C34. Furthermore,
we demonstrate that NSun3-dependent modification of
mt-tRNAMet is a necessary intermediate step towards the
formation of 5-formylcytosine (f5C) at this position. This study
demonstrates that methylation of mt-tRNAMet by NSun3 is an
important epitranscriptome modification, necessary for efficient
mitochondrial protein synthesis and respiratory function.
Results
Loss of NSUN3 in a patient with mitochondrial disease. We
studied a patient recruited in the German network for
mitochondrial disorders (mitoNET) who developed mitochon-
drial disease symptoms at the age of three months (combined
developmental disability, microcephaly, failure to thrive, recur-
rent increased lactate levels in plasma, muscular weakness,
proximal accentuated, external ophthalmoplegia and convergence
nystagmus) and presented with combined OXPHOS deficiency in
skeletal muscle (Fig. 1a, Supplementary Note 1). Using whole-
exome sequencing with previously described methodologies and
bioinformatic filtering pipelines18,19, we identified compound
heterozygous predicted loss-of-function variants in NSUN3
(Fig. 1b): (i) a 3,114 bp deletion (c.123-615_466þ 2155del)
removing the entire exon 3 and fragments of the flanking
introns, generating aberrant splicing between exons 2 and 4 and a
frameshift mutation (p.Glu42Valfs*11; Fig. 1c–e) and (ii) a point
mutation (c.295C4T) resulting in a premature stop codon
(p.Arg99*) (Fig. 1c–e).
Mitochondrial localization of NSun3. Since a large-scale
proteomic approach has suggested that NSun3 localizes to the
mitochondrial matrix17 and we detected mitochondrial respiratory
chain deficiencies in an individual with potentially pathogenic
NSUN3 variants we set out to confirm NSun3 as a mitochondrial
protein. A Flag-tagged version of the NSun3 protein (NSun3-Flag,
mRNA GenBank: NM_022072.3), transiently-expressed in HeLa
cells, colocalized with the mitochondrial protein TOM20 on
immunocytochemistry detection (Fig. 1f). Cellular fractionation
experiments of HeLa cells indicated that the endogenous NSun3 is
enriched within the mitochondrial fraction, along with a known
mitochondrial matrix protein mtSSB1 (Fig. 1g, lane 4). Both
NSun3 and mtSSB1 were resistant to proteinase K treatment of the
mitochondrial fraction, whereas in similar conditions the outer
membrane protein TOM22 was truncated by proteinase
K digestion (Fig. 1g, lane 5), confirming that NSun3 is localized
within mitochondria in human cells.
Impaired mitochondrial translation due to NSun3 deficiency.
The compound heterozygous NSUN3 gene variants are predicted to
result in a non-functional, truncated protein product (Fig. 1e).
Western blot analysis using primary human dermal fibroblasts
(hDFs) confirmed the lack of the full-length NSun3 protein in
patient-derived cells (Fig. 2a, mut/mut) that could be rescued upon
lentiviral transduction with complementary DNA (cDNA) encod-
ing a V5-tagged NSun3 construct (Fig. 2a, mut/mutþNSUN3).
We next asked whether the lack of NSun3 affected mito-
chondrial function in patient’s hDFs. The mitochondrial
respiratory chain activity was impaired in the absence of
NSun3 (Fig. 2b, Supplementary Note 1). The reduced oxygen
consumption rate in NSun3 mutant cells (mut/mut) was rescued
by re-expression of exogenous NSun3 cDNA (mut/mutþ
NSUN3). We further confirmed the compromised respiratory
chain performance of hDFs lacking the functional NSun3
protein by growing them in a medium containing galactose as
the sole carbon source, therefore forcing the cells to rely more
on mitochondrial ATP production. Under these conditions,
the patient-derived hDFs (mut/mut) had a lower growth rate
than wild-type cells (wt/wt); and this effect was rescued by
re-expression of NSun3 (mut/mutþNSUN3; Fig. 2c).
These results indicate that NSun3 is necessary for efficient
mitochondrial OXPHOS.
We next asked whether the lack of NSun3 affects mitochondrial
gene maintenance and expression. The mtDNA copy number was
unchanged between wt/wt and mut/mut hDFs (Fig. 2d), consistent
with mitochondrial biogenesis being unaffected by the absence of
NSun3. We next tested whether the lack of NSun3 affects mtRNA
expression by measuring mtRNA levels. In qPCR experiments, we
detected an increase in mitochondrial transcript levels (precursor
and mature) in mut/mut hDFs that was rescued to normal levels
upon NSUN3 cDNA re-expression (mut/mutþNSUN3) (Fig. 2e).
Northern blot analyses confirmed the increase in the levels of
mature mt-mRNAs and mt-rRNAs in NSUN3 mutant cells
(Supplementary Fig. 1a). High-resolution northern blot analysis
did not reveal any appreciable differences in expression levels of
mt-tRNAs in the absence of NSun3 (mut/mut; Fig. 2f), nor did it
show any effect on mt-tRNA aminoacylation (Supplementary
Fig. 1b). In contrast, measurement of mitochondrial translation by
incorporation of radioactively labelled methionine revealed that the
mitochondrial de novo protein synthesis rate was markedly
decreased in the absence of NSun3 (Fig. 2g,h, Supplementary
Fig. 1c). Lentiviral transduction of NSUN3 cDNA resulted in a
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12039
2 NATURE COMMUNICATIONS | 7:12039 | DOI: 10.1038/ncomms12039 | www.nature.com/naturecommunications
substantial increase of mitochondrial translation rate in
patient’s hDF (Fig. 2g,h, Supplementary Fig. 1c). The decrease
in mitochondrial protein synthesis rate in mut/mut cells
was accompanied with a reduction in the steady-state levels of
complex I (Supplementary Fig. 1d,e); complex I is often affected
predominately when expression of mtDNA in perturbed20. We
concluded that in the absence of NSun3 mitochondrial transcripts
are upregulated, possibly due to compensatory effects, yet the
loss-of-function mutations of NSun3 impair mitochondrial
protein synthesis. Thus, altogether these data show that NSun3 is
necessary for efficient mitochondrial translation, suggesting that an
NSUN3 defect is responsible for the combined OXPHOS deficiency
in the patient.
NSun3 methylates mitochondrial tRNAMet at position C34.
NSun3 shows sequence homology to proteins of the
NOL1/NOP2/Sun (NSun) domain-containing family (PFAM:
01189) that are class I S-adenosylmethionine-dependent
methyltransferases (AdoMet-MTase; Supplementary Fig. 2a).
Other members of this family have been implicated in
post-transcriptional cytosine-5 methylation (m5C) of RNA. We
recently utilized methylation-individual nucleotide resolution
crosslinking and immmunoprecipitation (miCLIP) in a
transcriptome-wide approach to identify NSun2-methylated
nucleosides21. Here we used this method to reveal RNA targets of
the related m5C RNA methyltransferase NSun3. All RNA:m5C
methyltransferases contain a catalytic domain with a common
structural core and the AdoMet-binding site (Supplementary
Fig. 2a). Two conserved active site cysteines, (TC1 and PC2), are
required for the transfer of the methyl group (Supplementary
Fig. 2a)22. Catalytic cysteine (C1) forms a covalent bond with the
cytosine pyrimidine ring. The second conserved cysteine (C2) is
required to break the covalent adduct and releases the methylated
RNA from the enzyme (Supplementary Fig. 2a,b). Mutating the
cysteine C2 to alanine (NSun3-C2A) results in the irreversible
formation of an RNA–protein complex at the methylation site
(Supplementary Fig. 2a–c)22–24. Such catalytic intermediate
RNA–protein complex can be immunoprecipitated and the
attached RNA identified by sequencing. Covalent crosslinking
of the catalytically inert protein to the cytosine it tries to
methylate, leaves a short peptide at this site and causes the reverse
transcriptase to stall25, so all sequence reads end around (but not
necessarily exactly at) the methylation site9,21. We performed
miCLIP following transfection of the NSun3-C2A catalytic
mutant cDNA construct into HEK293 cells (Supplementary
Fig. 2d). This analysis showed that, in contrast to NSun2,
which mainly methylates cytoplasmic tRNAs11,21, the vast
majority of NSun3 miCLIP detected sites mapped to mtRNAs
(Supplementary Fig. 2e,f, Supplementary Data 1), consistent with
mitochondrial localization of the protein. Analysis of miCLIP
reads revealed a broad spectrum of potential target sites in
mtRNA, however, a more substantial enrichment of sequences
specific for the following mitochondrial genes was observed: the
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MT-TM, coding for mt-tRNAMet (26% of all reads mapped to
mtDNA and 60% of all mitochondrial tRNA miCLIP loci),
MT-ND1, for mitochondrially encoded NADH dehydrogenase 1
(15% of all reads mapped to mtDNA), along with two other
mt-tRNAs genes, MT-TL1 (coding for mt-tRNALeu(UUR)) and
MT-TS2 (coding for mt-tRNASer(AGY)) (5% and 4.5% of
mtDNA-mapped reads, respectively; Fig. 3a, Supplementary
Data 1). Remarkably, miCLIP sequence reads corresponding to
the nuclear-encoded, cytoplasmic (ct-) initiator tRNA methionine
(ct-tRNAiMet) were also enriched (83% of all reads mapped to
nDNA; Supplementary Data 1). While these data suggest that
NSun3 methylates mitochondrial RNA, they also point towards
both the mitochondrial and cytoplasmic tRNAMet as key
substrates for the enzyme.
To provide further insights into NSun3 mtRNA targets, we
additionally performed ultraviolet crosslinking and immunopreci-
pitation coupled with high-throughput sequencing (HITS-CLIP)
using mitochondrial lysates of HEK293T cells. To compensate for
a possible bias caused by antibody–epitope interactions, we used a
NSun3-Flag construct in the HITS-CLIP assay (rather than c-myc
in the miCLIP approach). This analysis revealed that, among all
mitochondrial transcripts, only MT-TM-specific reads had a
significantly enriched read count (Supplementary Data 2)
compared with a control. As HITS-CLIP is able to map RNA-
protein binding footprint regions at a resolution of B30 to 60
nucleotides26, we looked at the exact positions of MT-TM-specific
reads. This analysis revealed that NSun3 targets predominantly the
mt-tRNAMet anticodon loop (Fig. 3b, Supplementary Fig. 2g–i).
We applied a third technique to determine which specific
cytidine residues are methylated by NSun3 and we examined the
differences in RNA m5C patterns on NSUN3 loss-of-function. To
this end, we performed high-throughput sequencing of cDNA
libraries obtained after bisulfite treatment of RNA of wild-type
hDFs (wt/wt), patient hDFs lacking the functional NSun3 protein
(mut/mut) and mut/mut hDFs expressing a NSUN3 cDNA
(mut/mutþNSUN3). The bisulfite RNA sequencing (BS RNA-
Seq) analysis revealed that methylation in mt-tRNAMet (MT-TM)
was decreased to background levels in NSUN3 mutant cells (mut/
mut), while other top mtRNAs with sites enriched by miCLIP
(Fig. 3a; MT-TL1, MT-TS2, MT-ND1) showed no changes in
the level of cytosine-5 methylation in NSUN3 mutant cells
(mut/mut), when compared with wt/wt or the cells transduced
with exogenous NSUN3 (mut/mutþNSUN3; Fig. 3b–i;
Supplementary Fig. 3a,b; Supplementary Data 3). We did not
detect m5Cs in the MT-ND1 transcript in any of the cell lines
examined (Supplementary Data 3, Supplementary Fig. 4a,b),
suggestive for non-specific miCLIP hit for this gene, possibly
owing to the structural features of the identified MT-ND1 RNA
region (Supplementary Fig. 4c), in combination with sub-optimal
expression levels of NSun3 in the miCLIP experiment. The m5C
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Student’s t-test. (c) Relative cell growth rate of wt/wt, mut/mut and mut/
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Coomassie blue stained gel as loading control. (h) Quantification of the
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detected in mt-RNAMet occurred at universal tRNA position 34
(‘wobble’ base) in the anticodon loop (corresponding to mtDNA
position 4432) and overlapped with the miCLIP and HITS-CLIP-
detected sites in this mt-tRNA (Fig. 3b–d). Although, we detected
m5C in mt-tRNALeu(UUR) (MT-TL1) and mt-tRNASer(AGY)
(MT-TS2), we did not uncover any appreciable differences in
this modification between wt/wt, mut/mut or mut/mutþNSUN3
hDFs (Fig. 3f,g,i,j) and the mt-tRNA methylation positions did
not overlap with miCLIP sites (Fig. 3e,h). The bisulfite RNA
sequencing also revealed m5C in other mt-tRNAs, namely
mt-tRNAHis, mt-tRNAGlu, mt-tRNAPhe (Supplementary
Fig. 3c–h). However, none of these other methylated mt-tRNAs
exhibited reduction in the m5C levels in the patient fibroblasts
(Supplementary Fig. 3c–h). We further analysed the BS RNA-Seq
reads to determine whether the ct-tRNAiMet, highly enriched in
the miCLIP experiments (Supplementary Data 1), is also a
target for NSun3. We detected m5C at position 48 of ct-tRNAiMet
(Supplementary Fig. 4d,e), however, we found no changes in the
m5C levels in the patient fibroblasts (Supplementary Fig. 4d).
This result is consistent with the previously published data
reporting m5C48 in ct-tRNAiMet being introduced by NSun2
(ref. 11). We deduced that miCLIP enrichment of ct-tRNAiMet by
NSun3 is likely to be caused by close sequence and structure
similarity of the anticodon loop of mt-tRNAMet and ct-tRNAiMet
(Supplementary Fig. 4f,g). In the miCLIP experiment,
overexpressed NSun3-C2A is released from mitochondria on cell
lysis, which allows for interaction with ct-tRNAiMet and a
subsequent pull-down. This interaction is prevented in vivo by
stringent regulation of NSun3 compartmentalization. Collectively,
the combined approach of miCLIP, HITS-CLIP and BS RNA-Seq
confirm that cytosine-5 methylation of mt-tRNAMet at position
34 is mediated by NSun3.
Methylation of mt-tRNAMet is necessary for f5C formation.
Although never shown in human mt-tRNA, several studies have
demonstrated the presence of f5C at position C34 of mature
mammalian mt-tRNAMet (refs 27,28). Since bisulfite treatment
does not distinguish between f5C and unmodified cytosines29
(Fig. 4a), we applied two high-throughput techniques to detect
f5C in mitochondrial RNA from wt/wt and mut/mut samples.
First, reduced bisulfite sequencing (RedBS-Seq) relies on the
chemical reduction of f5C to hm5C by NaBH4; hm5C is then
detected in the same manner as m5C (ref. 29). Second, O-
ethylhydroxylamine was used to protect f5C against conversion in
f5C chemically assisted bisulfite sequencing (fCAB-Seq)30.
Consistent with the previously published data for other
mammalian species, both techniques detected f5C34 in mt-
RNAMet in the wt/wt sample (36 and 38% for RedBS-Seq and
fCAB-seq, respectively). However, no f5C was detected in mut/
mut samples using either of the methods (Fig. 4b–e). We
concluded that methylation of position C34 by NSun3 is
necessary for f5C34 formation in mt-tRNAMet (Fig. 4f).
Discussion
Here we have identified the mitochondrial substrate for the
previously uncharacterized cytosine-5 RNA methyltransferase
NSun3, found mutated in a patient with mitochondrial disease.
The NSun3-null patient fibroblasts have a striking deficiency of
m5C and f5C at position 34 (‘wobble’ base) in the anticodon of
mt-tRNAMet, consistent with a precursor–product relationship for
these two modifications. We also show that this deficiency is
associated with impaired mitochondrial translation and OXPHOS.
The presence of m5C at position 34 has not been reported
previously in mammalian mt-tRNAMet (ref. 31). However, this
position has been known to contain 5-formylcytidine (f5C).
Although f5C has never been formally reported in human, this
modification has been considered as universal and detected in a
number of other species including cow, rat, chicken, frog, squid,
fruit fly and nematode27,28. Therefore, our finding of m5C34
modification in mt-tRNAMet as a key target for NSun3 might be
considered unexpected, as it would be mutually exclusive with the
previously reported f5C34 (cytidine carbon 5 is modified in both
cases). Despite the widespread occurrence of f5C34 in mt-tRNAMet,
the enzymatic activity responsible for its formation is unknown.
However, a recent in vivo isotope-tracing experiment in a mouse
model has revealed that m5C in RNA can be oxidatively
metabolized first to 5-hydroxymethylcytosine (hm5C) and
subsequently to f5C (ref. 32). With this in mind, we analysed f5C
content in mt-tRNAMet in NSun3-null and control cells. We found
that, although f5C34 is indeed present in mt-tRNAMet in wild-type
human mitochondria, no f5C was detected in NSun3-null patient
samples. The proportion of mt-tRNAMet that contain f5C34 in
human dermal fibroblasts has not been determined previously. Our
study revealed thatB36 to 38% of the mt-tRNAMet-specific RNA-
Seq reads contain f5C34 in wt/wt cells. This proportion might be
biased by incomplete reduction of f5C to hm5C by NaBH4 or not
complete protection of f5C by O-ethylhydroxylamine, therefore the
actual percentage of f5C34 in the mature mt-tRNAMet might be
higher. Nonetheless, the complete lack of f5C in the NSun3-null
cells is consistent with methylation of C34 by NSun3 being
necessary for formation of f5C34 in mt-tRNAMet (Fig. 4f).
The dynamics and oxidative metabolism of C5-methylation has
recently been the subject of intense investigation in DNA. The
10–11 translocation (Tet) family of dioxygenases mediates the
sequential removal of m5dC through an oxidative pathway
involving the intermediates hm5dC and f5dC (ref. 33). Further
studies have demonstrated that f5dC can be a stable DNA
modification, suggesting that it has its own unique biological
function in addition to being an intermediate in m5dC removal34.
Tet-mediated oxidation of m5C to hm5C and f5C in RNA has
been shown in vitro, although much less efficient than the
corresponding oxidation of m5dC in DNA35. Further studies will
be necessary to identify a dioxygenase mediating m5C to f5C
conversion in human mitochondria and to establish its regulatory
mechanisms (Fig. 4f).
Why has m5C34 in mt-tRNAMet not been detected in previous
studies, despite relatively high detection levels in BS RNA-Seq? In
the reports on post-transcriptional modifications of mt-tRNAMet
only mature mt-tRNA species were analysed. In contrast, our
miCLIP and BS RNA-Seq approaches are able to detect m5C both
in precursor and mature human mt-tRNAMet. We consider that
m5C could be introduced early in the mtRNA maturation pathway,
so that predominately precursor mtRNA contains this modifica-
tion. This is in line with other published work, where f5C34 has
been detected in addition to m5C34 in mammalian ct-tRNAsLeu(-
CAA). In this case, another member of the NOL1/NOP2/Sun family,
NSun2, is responsible for catalysing ct-tRNAsLeu(CAA) m5C34 with
a preference for precursor tRNA11,12,36. Furthermore, the BS RNA-
Seq method used is unable to distinguish between m5C and its
oxidized derivative hm5C, therefore the NSun3-mediated
methylation consistently detected at B30% by BS RNA-Seq of
wt/wt cells (Fig. 3c) might be overestimated.
How does the lack of NSun3-mediated mt-tRNAMet C34
methylation affect mitochondrial translation? Mitochondrial
protein synthesis displays unique features as compared with its
cytoplasmic counterpart. In human mitochondrial mRNAs,
methionine is encoded either by the universal AUG or the
unconventional AUA (isoleucine in the universal genetic code).
Also, mitochondrial translation in many organisms, including
humans, occasionally initiates with methionine encoded by the
universal isoleucine codons AUU or AUC. There is only one
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12039
6 NATURE COMMUNICATIONS | 7:12039 | DOI: 10.1038/ncomms12039 | www.nature.com/naturecommunications
mitochondrial tRNAMet that decodes all of these AUN
codons27,28. It has been shown in vitro that f5C34 in human
mt-RNAMet allows for decoding of AUG and the non-traditional
codons AUA, AUU and AUC28,37. Our data on methylation by
NSun3 providing a necessary precursor for f5C34 in mt-RNAMet,
as well as the general mitochondrial translation defect observed in
patient-derived NSun3-null cells, are compatible with the existing
evidence on less efficient decoding by unmodified mt-RNAMet.
Our study also constitutes a valuable resource of human
mt-tRNA modifications as we provide previously unreported
modifications. We detected eight cytosine-5 methylations in six
mitochondrial tRNAs. We confirm the presence of five cytosine
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Figure 4 | m5C34 in mt-tRNAMet is a necessary precursor for f5C34. (a) Heatmaps of BS RNA-Seq reads for mt-tRNAMet (MT-TM) for wt/wt and mut/
mut cells, showing cytosines of individual reads (on y axis). Methylated (and hydroxymethylated) cytosines are shown in orange, while unmodified or
formylated cytosines are shown in grey (x axis). (b) Heatmaps of fCAB RNA-Seq reads for mt-tRNAMet (MT-TM) for wt/wt and mut/mut cells, showing
cytosines of individual reads (on y axis). Purple indicates methylated, hydroxymethylated or formylated, while unmodified cytosines are shown in grey.
(c) Heatmaps of RedBS RNA-Seq for mt-tRNAMet (MT-TM) for wt/wt and mut/mut cells showing cytosines of individual reads (on y axis). Purple indicates
methylated, hydroxymethylated or formylated, while unmodified cytosines are shown in grey. (d) Summary of the fCAB RNA-Seq results for
wt/wt and mut/mut cells. (e) Summary of the RedBS RNA-Seq results for wt/wt and mut/mut cells. (f) Graphical overview of the mt-tRNAMet C34
formylation pathway. NSun3 methylates unmodified C34 into m5C34, which is then further processed (responsible enzyme(s) unknown) into f5C34.
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methylations that were described previously in human and bovine
mt-tRNA: m5C49 of mt-tRNAGlu, m5C48 of mt-tRNALeu(UUR)
and m5C48, -49, -50 of mt-tRNASer(AGY) (refs 31,38,39). Apart
from m5C34 of mt-RNAMet, we also detect the presence of two
m5C modifications in human mt-tRNA that have not been
reported previously: m5C47 of mt-tRNAHis and m5C47 mt-
tRNAPhe, both occurring in the variable region of the tRNAs
(Supplementary Table 1).
In summary, we have identified NSun3 as a novel human m5C
RNA methyltransferase and show its target specificity,
mitochondrial tRNAMet. Mutations in NSUN3, found in a patient
with mitochondrial disease, were associated with hypomethyla-
tion and the absence of formylation of cytosine residue at position
34 of mitochondrial tRNAMet leading to impaired mitochondrial
translation. This is highly suggestive of a causal link between
mutations in NSUN3 and mitochondrial disease. Our study
highlights the importance of epitranscriptome modification for
optimized mitochondrial protein translation and faithful cellular
function, highlighting a novel role for m5C as precursor of f5C in
human mitochondria.
Note added in proof: After we submitted this report, similar
conclusions on the role of NSUN3 were reported (Nakano et al.
Nat. Chem. Biol. 2016 May 23. doi:10.1038/nchembio.2099).
Methods
Detection of NSUN3 variants. Whole-exome sequencing was performed using a
SureSelect Human All Exon 50Mb Kit (Agilent) for enrichment and a HiSeq2500
(Illumina) for sequencing18 Read alignment to the human genome (UCSC Genome
Browser build hg19) was done with Burrows–Wheeler Aligner (BWA, v.0.7.5a) and
single-nucleotide variants and small insertions and deletions were detected with
BWA (v.0.7.5a) and SAMtools (version 0.1.19). Given that mitochondrial disorders
are rare, we excluded variants with a frequency 40.1% in 7,000 control exomes
and public databases. On the basis of a recessive model of inheritance, we next
searched for genes carrying predicted homozygous or compound heterozygous
nonsynonymous variants followed by a filter for genes encoding proteins with a
predicted mitochondrial localization40. Written informed consent of diagnostic and
research studies was obtained from all individuals investigated or their guardians, and
the ethics committee of the Technische Universita¨t Mu¨nchen approved the study.
NSun3 cDNA constructs. Full-length cDNA constructs for NSun3 in the
pCMV6-Entry-Myc vector were obtained from OriGene. Site-directed mutagenesis
to generate the miCLIP-mutant was performed using the QuikChange II
Site-Directed Mutagenesis Kit from Agilent as per the manufacturer’s instructions
(Supplementary Table 2). Overexpression of NSun3 in mut/mut human fibroblasts
was performed through lentiviral gene transfer using the ViraPower HiPerform
Lentiviral TOPO Expression Kit (Life Technologies). The full-length NSun3 cDNA
was obtained from DNASU Plasmid Repository (HsCD00439330) and was cloned
into the pLenti6.3/V5-TOPO vector system (Thermo Fisher) (Supplementary
Table 2). For NSun3 overexpression in HeLa cells, full-length cDNA was cloned
into a plasmid encoding FLAG.STREP2-tag and the resulting fragment was cloned
into pcDNA5-FST2 as previously described41 (Supplementary Table 2).
Cell culture and transfection. HEK293 cells, HeLa cells and primary hDFs were
grown in DMEM (Life Technologies) supplemented with 10% fetal bovine serum at
37 C in a humidified atmosphere with 5% CO2. HEK293 cells were transfected
with NSun3 wild-type or NSun3 miCLIP-mutant constructs using Lipofectamine
2000 (Life Technologies) and collected 24 h later. For immunofluorescence studies,
HeLa cells were transfected with the NSun3 FLAG.STREP2-tagged construct using
Lipofectamine 2000 and were analysed 48 h post transfection.
Lentiviral particles containing the packaged pLenti NSun3 and NSun3-V5
expression constructs were generated by cotransfecting HEK 293FT cells with the
packaging plasmid mix and the NSun3 or NSun3-V5 expression construct,
respectively using Lipofectamine 2000. Twenty four hours after transfection the
medium containing the DNA- Lipofectamine 2000 mix was replaced with high
glucose DMEM supplemented with 10% FBS and the cells were incubated for
another 48 h. The virus-containing supernatant was collected and used for
subsequent transduction of control and patient fibroblasts. Stably transduced
fibroblasts were selected using Blasticidin (Thermo Fisher) for at least 2 weeks and
kept under selection for any further analysis.
Flp-In T-Rex HEK293T cells were maintained in DMEM supplemented with 10%
tetracycline-free fetal bovine serum (Biochrom AG), 100mgml 1 Zeocin and
15mgml 1 Blasticidin (Life Technologies). Cells were stably transfected with the
NSun3 FLAG.STREP2-tagged construct with Lipofectamine 2000. After 1 day, medium
with selective antibiotics (50mgml 1 hygromycin and 15mgml 1 blasticidin (Life
Technologies) was used to select cells with the stably integrated transgene.
For cell proliferation measurements cells were plated at a density of 50,000
fibroblasts per well of a six-well plate and confluency was measured every 6 h using
an IncuCyte ZOOM live-cell imaging system (Essen BioScience).
Respiratory chain assay. Fibroblasts were seeded at a density of 20,000 cells per
well in 80ml of culture media in a XF 96-well cell culture microplate (Seahorse
Bioscience) and incubated overnight at 37 C in 5% CO2. Culture medium was
replaced with 180ml of bicarbonate-free DMEM and cells were incubated at 37 C for
30min prior measurement. Oxygen consumption rate was measured using a XF96
Extracellular Flux Analyser (Seahorse Biosciences). Oxygen consumption rate was
determined with no additions; after addition of oligomycin (1mM); after addition of
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 0,4mM); and after
addition of rotenone (2mM) (additives purchased from Sigma at highest quality).
Immunodetection of proteins. Immunofluorescence analysis and cell
fractionation were performed essentially as described previously42. In brief, HeLa
cells were transiently transfected to express NSun3-FLAG-Strep2 for 2 days. Cells
were fixed with 4% formaldehyde for 15min and permeabilized with 1% TritonX
for 5min before blocking with 10% fetal bovine serum for 1 h. The following
primary antibodies were used: mouse anti-FLAG IgG (Sigma F3165, 1/200) and
rabbit anti-TOM20 (Santa Cruz Biotechnology sc-11415, 1/500). Secondary
antibodies were Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 594 goat
anti-mouse (both Life Technologies, 1/1000). Next, cells were mounted with DAPI-
containing ProLong Gold Antifade (Life Technologies) and immunofluorescence
images were captured using a Zeiss Observer microscope and Apotome system.
For immunoblot analysis, equal amounts of proteins corresponding to total cell
lysates or protein fractions were subjected to SDS–PAGE electrophoresis, semi-dry
transferred to nitrocellulose membranes, blocked in 5% non-fat milk (Marvel) in
PBS for 1 h and incubated with specific primary antibodies in 5% non-fat milk in
PBS for 2 h or overnight. The blots were further incubated with HRP-conjugated
goat anti-rabbit and anti-mouse (Promega W401B and W4028, 1/2,000) for 1 h and
visualized using ECL (GE Healthcare). The following primary antibodies were used:
NSun3 (Sigma Aldrich HPA036181, 1/250), TOM22 (Abcam ab10436, 1/2,000),
GAPDH (Abcam ab9482, 1/2,000), mt-SSB1 (kindly donated by Prof. D. Kang,
1/4,000), Histone H3 (Abcam ab1791, 1/4,000), beta actin (Sigma A1978, 1/75,000)
and Total OXPHOS Human WB Antibody Cocktail (Abcam ab110411, 1/1,000).
Mitochondrial DNA copy number and deletion analysis. Total cellular DNA
was isolated from fibroblasts using a DNeasy Blood and Tissue kit (Qiagen)
according to the manufacturer’s protocol. Copy numbers of mtDNA were deter-
mined by quantitative PCR43. All primers can be found in Supplementary Table 2.
Mitochondrial transcript analysis. Total RNA from fibroblasts was extracted
using TRIzol and treated with Turbo DNase according to the manufacturer’s
protocol. For PCR, 2mg of DNase treated RNA was reverse transcribed using
Omniscript RT kit (Qiagen) with 0.5mM random hexamers and 0.5mM oligo dT
primers. Primer sequences can be found in Supplementary Table 2. For northern
blot analysis, total RNA was resolved on 1% agarose gels containing 0.7M for-
maldehyde in 1 MOPS buffer (mt-mRNAs) or on 5% UREA–PAGE (mt-tRNAs),
transferred to a nylon membrane in 2 SSC, ultraviolet-crosslinked to the mem-
brane and hybridized with radioactively labelled PCR fragments corresponding to
appropriate regions of mtDNA (mt-mRNAs) or T7-transcribed radioactive RNA-
probes (mt-tRNAs). Mt-tRNA aminoacylation analysis was performed as previously
described44. Briefly, total RNA was resuspended in 10mMNaOAc (pH 5.0) and kept
at 4 C to preserve the aminoacylation state. For deacylated control, the pellet was
resuspended in 200mM Tris-HCl (pH 9.5) and incubated for 5min at 75 C,
followed by RNA precipitation and resuspension in 10mM NaOAc (pH 5.0). Next,
15mg of RNA was separated on a 6.5% polyacrylamide gel (19:1 acrylamide:
bisacrylamide) containing 8M urea in 0.1M NaOAc (pH 5.0) at 4 C and
electroblotted (Bio-Rad, Trans-Blot Cell) onto a nylon transfer membrane (Hybond,
GE). Following ultraviolet crosslinking, the membrane was hybridized with
appropriate radiolabelled riboprobes, washed and imaged using a PhosphorImager.
35S-methionine metabolic labelling of mitochondrial proteins. Metabolic
labelling was performed essentially as described previously (ref. 45). In brief,
fibroblasts were grown as described above until at 80% confluency, then medium
was replaced with methionine/cysteine-free DMEM (Sigma) supplemented with
2mM L-glutamine, 48mgml 1 cysteine and 50 mgml 1 uridine for 2 10min,
followed by methionine/cysteine-free DMEM medium containing 10% (v/v)
dialysed FCS and emetine dihydrochloride (100 mgml 1) to inhibit cytosolic
translation for 10min before addition of 120mCiml 1 of [35S]-methionine.
Labelling was performed for 15min. SDS–PAGE was performed on 30 mg of
protein and products were imaged using a PhosphorImager.
Methylation-iCLIP (miCLIP). For miCLIP experiments, collected cells were lysed
in lysis buffer consisting of 50mM Tris-HCL pH 7.4, 100mM NaCl, 1% NP-40,
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0.1% SDS, 0.5% sodium deoxycholate. Lysates were then treated with high
concentration of DNase and low concentration of RNaseI to partially fragment
RNAs. Lysates were cleared by centrifugation at 13,000 r.p.m. for 15min at 40 C
and then incubated with Protein G Dynabeads (Life Technologies) in the
presence of an anti-Myc antibody (9E10, Sigma). Following stringent washing,
30-end dephosphorylation was performed with T4 PNK (New England Biolabs)
before addition of a preadenylated linker using RNA ligase (New England Biolabs).
50-end labelling was then performed using T4 PNK and 32P-ATP before
protein–RNA complexes were eluted and run on denaturing gels. Next,
nitrocellulose transfer was performed and the radioactive signal was used to dissect
nitrocellulose pieces that contained NSun2-partially digested RNA complexes.
RNA was recovered by incubating the nitrocellulose pieces in a buffer containing
Proteinase K and 3.5M urea. Reverse transcription was performed using
oligonucleotides containing two inversely oriented adaptor regions separated by a
BamHI restriction site. cDNAs were size-purified on TBE-Urea gels before being
circularized by CircLigase II (Epicentre). Circularized cDNAs were then annealed
to an oligonucleotide complementary to the BamHI site and then BamHI digested.
Linearized cDNAs were then PCR-amplified using primers complementary to the
adaptor regions using 25 cycles of PCR. Libraries were then subjected to high-
throughput sequencing using the Illumina HiSeq2000 platform. The details of the
constructs used in the miCLIP experiments are provided in Supplementary Table 2.
Processing and mapping of miCLIP reads. To reduce amplification bias, the
primers used for reverse transcription during miCLIP experiments were designed
to include a six-nucleotide random barcode at positions 1–3 and 8–10 to enable
tracing of individual cDNAs. Reads were demultiplexed using the experimental
barcode at positions 4–7, and reads with identical random barcodes, representing
PCR products, were filtered. The number of different random barcodes for each
unique read, which represented cDNA counts, was stored for further analysis.
Barcodes were trimmed from the 50-end, and the adaptor sequence ‘50-AGATC
GGAAGAGCGGTTCAG-30 ’ from the 30-end of the reads with cutadapt
(ref. 46; options: ‘-O 4 –e 0.06’), and only reads with a minimal length of 18
nucleotides (nt) were retained.
Trimmed miCLIP reads were mapped to the human reference genome (UCSC
GRCh37/hg19) by using bowtie (ref. 47) with parameters ‘–m 1 –v 1 –best –strata’ to
select uniquely mapping reads allowing one mismatch. Our initial analysis showed
that miCLIP reads truncated predominantly at single cytosines. Methylation sites
were thus inferred from miCLIP read truncation positions by assigning the read
counts to the closest cytosine within±2 nt of the truncation site. Pooled read counts
per cytosine were normalized per million uniquely mapping reads (RPM). If not
stated otherwise, only high-confidence methylation sites with normalized read
counts450 RPM in at least two out of three replicates were selected for downstream
analyses. Transcript annotations were performed based on ENSEMBL annotations
(ENSEMBL 74).
RNA bisulfite sequencing (BS RNA-Seq). After enrichment for mitochondria by
differential centrifugation in homogenization buffer (10mM Tris-HCl (pH 7.4),
0.6M mannitol, 1mM EDTA), RNA was extracted from NSun3 patient primary
fibroblasts and wild-type controls and DNase and Ribo-zero gold (Illumina)
treated. Bisulfite conversion of the remaining RNA fraction was performed using
the Imprint DNA Modification kit (Sigma). The reaction mixture was incubated for
three cycles of 5min at 90 C followed by 1 h at 60 C and then desalted with Micro
Bio-spin 6 chromatography columns (Bio-Rad). RNA was desulphonated by
adding an equal volume of 1M Tris (pH 9.0) and incubated for 1 h at 37 C,
followed by ethanol precipitation. About 120 ng of bisulfite-converted RNA was
end repaired with T4 PNK (New England Biolabs) and used for library generation,
following the manufacturer’s protocol (TruSeq Small RNA library preparation kit
(Illumina)). Quality and concentration was assessed with a D1000 Screentape for
TapeStation (Agilent). Libraries were subjected to high-throughput sequencing
using the Illumina MiSeq/HiSeq platform.
fCAB RNA-Seq and RedBS RNA-Seq. For both techniques, 1 mg of mitochondrial
enriched, DNase and Ribo Zero treated RNA of patient and wild-type fibroblasts
was used as starting material. BS RNA-Seq was performed in parallel as a control.
Chemical reduction of f5C in RedBS RNA-Seq was accomplished by adding 20 ml
freshly prepared NaBH4 (40mM). After 15min incubation at room temperature,
another 20ml NaBH4 was added for a further 15min (ref. 29). To protect f5C
against bisulfite conversion in fCAB RNA-Seq, RNA was incubated with 10mM
O-ethylhydroxylamine for 2 h at 37 C (ref. 30). Further bisulfite treatment and
library preparation was similar to BS RNA-Seq.
UV crosslinking and immunoprecipitation (HITS-CLIP). A covalent bond
between NSun3 protein and RNA in HEK293T cells expressing NSun3.-
FLAG.STREP2 was induced by irradiation with ultraviolet (UV) light
(250mJ cm 2). After cell collection, mitochondria were extracted by differential
centrifugation. Pelleted mitochondria were lysed and RNA was partially digested
with 4 ml micrococcal nuclease (NEB) for 15min at room temperature in the
presence of 3 ml TURBO DNase. The reaction was stopped by adding 12 ml
SUPERasin (ThermoFisher Scientific). After immunoprecipitation with FLAG M2
affinity beads (Sigma) and elution with FLAG peptide as recommended by the
manufacturer, proteins were digested with 4mgml 1 Proteinase K. RNA was end
repaired with Antarctic Phosphatase and T4 Polynucleotide Kinase. Library
preparation and high-throughput sequencing were similar as for BS RNA-Seq.
Processing and Mapping of BS RNA-Seq reads. BS RNA-Seq reads were quality
trimmed, adaptors were removed and the reads were mapped to the computationally
bisulfite-converted human reference genomes (UCSC GRCh37/hg19) with Bismark
(ref. 48; parameters: human: –non-directional –n 1 –l 40). Methylation levels for all
cytosines with a coverage of45 reads (5 ) were inferred with the Bismark
methylation_extractor tool. Methylation levels were compiled with and without
removing potential PCR duplicates to account for tRNA fragments shorter than read
length.
Processing and mapping of HITS-CLIP data. Quality trimming and 30-end
adaptor clipping of sequenced reads were performed simultaneously with Trim
galore! (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore) Reads
longer than 20 nt were aligned to the human reference genome (hg19 with mtDNA
replaced with rCRS) with Bowtie2 (ref. 49). After counting with Rsubread50 and
normalization, reads from NSun3 overexpression samples were compared with
reads of an unrelated protein (ENSG00000182362) with EdgeR (ExactTest with
dispersion 0.1)51.
Processing and mapping of fCAB RNA-Seq and RedBS RNA-Seq data. BS
RNA-Seq, fCab RNA-Seq and RedBS RNA-Seq data were pre-processed (both
quality trimming and adaptor removal) with Trim Galore! Reads longer than 20 nt
were mapped to the computationally bisulfite-converted human mitochondrial
genome (NC_012920) with Bismark49.
Data availbility. Source data are provided in Supplementary Fig. 5 and
Supplementary Fig. 6. The accession number sequencing data is available from the
Gene expression Omnibus (GEO) with accession number GSE66012. All
sequencing data related to the patient fibroblasts is available at the European
Genome-phenome Archive with accession code EGAS00001000164. The authors
declare that the data supporting the findings of this study are available within the
article and its Supplementary Information files.
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